

## 2019-2020 RSV (Synagis) Immunization

December 6, 2019 Page 1 of 3

Dear Care1st Providers and Staff:

As RSV season approaches, it is important to make arrangements to ensure that children who need Synagis® receive injections. Care1st will work with your office to authorize and obtain Synagis® with no out of pocket cost. Synagis season for 2019/2020 is November through April.

The guidelines for Synagis® administration are included on the <u>Care1st RSV Prophylaxis Eligibility Assessment Form</u> (i.e. Care1st Synagis Form) and is attached for your reference. The Care1st Synagis Form will also be used as the prior authorization form. <u>All</u> Synagis® requests require prior authorization. To obtain prior authorization:

- Please complete the Care1st RSV Prophylaxis Eligibility Assessment Form and <u>fax it to</u> <u>602.778.8387 with progress notes</u>. We will review and process your request as quickly as possible.
- <u>In Maricopa County</u>: once your request is approved, members may receive the immunization through:
  - Coram Health Infusion (4310 E. Cotton Center Blvd., Suite 110, Phoenix, AZ 85040)
     OR
  - In-home Nurse Administration (in conjunction with Coram/CVS Specialty) OR
  - Physician office setting, you may obtain Synagis from either:
    - Exactus Pharmacy (1-866-458-9246) OR
    - CVS Specialty Pharmacies (1-800-237-2767 OR 1-866-387-2573)
- <u>Outside Maricopa County:</u> administer Synagis in the office setting, once your request is approved, please contact one of the Specialty Pharmacies below to coordinate delivery:
  - Exactus Pharmacy (1-866-458-9246) OR
  - CVS Specialty Pharmacy (1-800-237-2767 OR 1-866-387-2573)
- The Care1st RSV (Synagis) Form is attached and also available on our website <u>www.care1staz.com</u> under the Forms section of the Provider menu.

Please contact the *Care1st Pharmacy Department at 602.778.1800 or 1.866.560.4042 (Options 5, 5)* if you have any questions

## Thanks!



## RSV (SYNAGIS) ELIGIBILITY ASSESSMENT FORM

FAX TO: Care1st Pharmacy Department 602.778.8387

Questions: 602.779.1800 (Option 5,5)

Six Simple Steps to Submitting a Referral **PATIENT INFORMATION** (Complete or include demographic sheet) \_\_\_\_\_Address: City, State, ZIP: Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below) Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone. Primary Phone: \_\_\_\_\_ Alternate Phone: \_\_\_\_\_ DOB: \_\_\_\_ Gender: \_ Male \_\_ Female Email: \_\_\_\_\_ Last Four of SSN: \_\_\_\_ Primary Language: \_\_\_\_ 2 PRESCRIBER INFORMATION Prescriber's Name: \_\_\_ State License #: \_\_\_\_\_ DEA #: Group or Hospital: NPI #: \_\_ \_\_\_\_\_ City, State, ZIP: \_\_\_\_\_ Address: Phone: \_\_\_ Fax\_\_\_\_\_ Contact Person: \_\_\_\_\_ Contact's Phone: \_\_\_\_\_ INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back) Prescription Card: ID#: BIN: PCN: Group: Name of Insurer: \_\_\_ Medical Insurance: \_\_\_\_\_ID#: \_\_\_\_\_\_ Name of Insurer: \_\_\_\_\_\_ Phone: \_\_\_\_\_ Subscriber: \_\_\_\_\_ Secondary Insurance: Subscriber: \_\_ ID#: \_\_\_\_\_\_ Phone: \_\_\_\_\_\_ DIAGNOSIS AND CLINICAL INFORMATION Needs by Date: \_\_\_\_\_ Expected date of first injection: \_\_\_\_\_ Ship to: ☐ Patient ☐ Office ☐ Other: Diagnosis (ICD-10): 23 wks (P07.22) 24 wks (P07.23) Gestational Age: <a> < 23</a> wks (P07.21) 25 wks (P07.24) 26 wks (P07.25) 27 wks (P07.26) 28 wks (P07.31) 29 wks (P07.32) ☐ 30 wks (P07.33) ☐ 34 wks (P07.37) 31 wks (P07.34) 32 wks (P07.35) 33 wks (P07.36) ☐ 35 wks (P07.38) Nursing: ☐ No nursing coordination ☐ Yes, CVS Specialty® to coordinate home health nurse visit for injection Chronic Respiratory Disease Arising in the Perinatal Period: ☐ Wilson-Mikity Syndrome (P27.0) ☐ Bronchopulmonary Dysplasia originating in the perinatal period (P27.1) Other chronic respiratory disease originating in the perinatal period (P27.8) Congenital Abnormality of Respiratory System: ☐ Congentical Subglottic Stenosis (Q31.1) ☐ Other Congenital Malformations of Trachea (Q32.1) ☐ Laryngocele (Q31.3) Other Congenital Malformations of Bronchus (Q32.4) ☐ Other Congenital Malformations of Larynx (Q31.8) ☐ Congenital Cystic Lung (Q33.0)

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record.

## 2019-2020 Synagis® Seasonal Respiratory Syncytial Virus Enrollment Form

| Chronic Lung Disease (CLD):    < 12 months of age with CLD* AND continues to require medical support during the 6-month period before second RSV season   Chronic corticosteroids (drugs/dates)   Chronic corticosteroids (drugs/dates)   Bronchodilators (drugs/dates)   Bronchodilators (drugs/dates)   Congenital Heart Disease (CHD):   < 12 months of age at start of season with hemodynamically significant CHD such as:   Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates)   Gurgery date)   Woderate to severe pulmonary hypertension   Other: describe   Gugnosis   Alimay/Neuro-muscular Conditions:   < 12 months of age at start of season and compromised handling of secretions AND due to   Significant abnormality of the airway (attach clinical notes)   Neuromuscular condition (attach clinical notes)   PRESCRIPTION INFORMATION   DOSE & DIRECTIONS   Quantity (St to service)   Output (Dome viels and part)   Dose & Directions   Quantity (St to service)   Output (Dome viels and part)   Dose & Directions   Quantity (St to service)   Country (St to service)   Dose & Directions   Quantity (St to service)   Characteristics   Chronic corticosteroids (drugs/dates)   Chronic cortico | carrie     |
|--|------------|
| Patient's Gestational Age (required):  |            |
| Patient's Gestational Age (required):weeksdays Patient's Birth Weight:g / kg / lbs (please circle)   |            |
| Date Recorded:   |            |
| Date Recorded:   | cle)       |
| Did patient receive Synagis last season?   |            |
| Multiple births:  No  Yes  Enter names of Synagis candidates (submit separate enrollment forms):  Daycare attendance:  No  Yes  School-age siblings in home:  No  Yes  NiCU name and include NiCU summary:  Medical conditions: 2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines  Chronic Lung Disease (CLD):  Medical conditions: 2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines  Chronic Lung Disease (CLD):  Provided Support during the 6-month period before second RSV season  Supplemental oxygen (dates)  Provided Support during the 6-month period before second RSV season  Provided Supplemental oxygen (dates)  Provided Support during the 6-month period before second RSV season  Provided Supplemental Oxygen (dates)  Provided Support during the 6-month period before second RSV season  Provided Support during the 6-month period before second RSV season  Provided Supplemental Oxygen (dates)  Provided Support during the 6-month period before second RSV season  Provided Support Supp |            |
| Daycare attendance:  No  Yes  School-age siblings in home:  No  Yes  NICU history:  No  Yes  If yes, NICU name and include NICU summarry:  Medical conditions not listed below:  Medical Conditions: 2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines  Chronic Lung Disease (CLD):  Medical Conditions:  Climital Conditions: 2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines  Chronic Lung Disease (CLD):  Medical Conditions of age with CLD* AND continues to require medical support during the 6-month period before second RSV season  Disease and age with CLD* AND continues to require medical support during the 6-month period before second RSV season  Disease  (ChD):  Promic corticosteroids (drugs/dates)  Promic corticosteroids (drugs/dates)  Promic Conferent University (drugs/dates)  Promic Conferent University (drugs/dates)  Promic Conferent University (drugs/dates)  Promic Congenital Heart Disease (CHD):  Such as:  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as:  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as:  Such as the first 28 days after the Congenital Heart Disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates)  Such as a such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  Such as the first 28 days after the Congenital Heart Disease (CHD):  S |            |
| NICU history: No Yes If yes, NICU name and include NICU summary: Allergies: Medical conditions not listed below: Clinical Conditions: 2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines Chronic Lung Disease (CLD):    < 12 months of age with CLD* AND continues to require medical support during the 6-month period before second RSV seasor   Supplemental oxygen (dates)  |            |
| Allergies:   |            |
| Chronic Lung Disease (CLD):    < 12 months of age with CLD* AND continues to require medical support during the 6-month period before second RSV season   Chronic corticosteroids (drugs/dates)   Chronic corticosteroids (drugs/dates)   Bronchodilators (drugs/dates)   Bronchodilators (drugs/dates)   Chronic corticosteroids (drugs/dates)   Bronchodilators (drugs/dates)   Congenital Heart Disease (CHD):   < 12 months of age at start of season with hemodynamically significant CHD such as:   Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates)   (surgery date)   Moderate to severe pulmonary hypertension   Other: describe   Cyanotic Heart Disease: diagnosis   Airway/Neuro-muscular Conditions:   < 12 months of age at start of season and compromised handling of secretions AND due to   Significant abnormality of the airway (attach clinical notes)   Neuromuscular condition (attach clinical notes)   Prematurity:   < GA 28 wks, 6 days AND < 12 months at start of season   Other conditions:   Other medical history (describe)   DOSE & DIRECTIONS   Quantity/R   Quantity/R   Quantity/R   Synagis   Direct 15 mg/kg IM one time per month  |            |
| Chronic Lung Disease (CLD):  |            |
| < 12 months of age with CLD*     < 24 months of age with CLD* AND continues to require medical support during the 6-month period before second RSV seasor     Supplemental oxygen (dates)   Chronic corticosteroids (drugs/dates)     Diuretic therapy (drugs/dates)   Bronchodilators (drugs/dates)     *CLD of prematurely defined as gestational age < 31 weeks, 6 days AND requirement for 21% oxygen for at least the first 28 days after to 21% oxygen for at least the first 28 days after to the first 28 days after to 21% oxygen for at l    |            |
| Supplemental oxygen (dates)  |            |
| Supplemental oxygen (dates)  | η ΔΝΠ      |
| *CLD of prematurely defined as gestational age < 31 weeks, 6 days AND requirement for 21% oxygen for at least the first 28 days after to the congenital Heart Disease (CHD): <p>&lt; 12 months of age at start of season with hemodynamically significant CHD such as:</p> Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates)  | 117040     |
| *CLD of prematurely defined as gestational age < 31 weeks, 6 days AND requirement for 21% oxygen for at least the first 28 days after bt Congenital Heart Disease (CHD):    < 12 months of age at start of season with hemodynamically significant CHD such as:   Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates)   |            |
| Congenital Heart Disease (CHD):  | irth       |
| Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates) (surgery date)    Moderate to severe pulmonary hypertension    Other: describe    Cyanotic Heart Disease: diagnosis    Airway/Neuro-muscular Conditions:    < 12 months of age at start of season and compromised handling of secretions AND due to    Significant abnormality of the airway (attach clinical notes)   Neuromuscular condition (attach clinical notes)    Prematurity:   < GA 28 wks, 6 days AND < 12 months at start of season    Other conditions:   Other medical history (describe)    PRESCRIPTION INFORMATION    MEDICATION   STRENGTH   DOSE & DIRECTIONS    Quantity: QS to general conditions   Quantity: QS to general conditions    Quantity: QS to general conditions   Inject 15 mg/kg IM one time per month    Other conditions   Other medical history (describe)    Synagis   Inject 15 mg/kg IM one time per month    Other conditions   Other medical history (describe)    Other conditions   Inject 15 mg/kg IM one time per month    Other conditions   Other medical history (describe)    Other conditions   Inject 15 mg/kg IM one time per month    Other conditions   Other medical history (describe)    Other conditions                                | 11 (1)     |
| Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates) (surgery date)    Moderate to severe pulmonary hypertension    Other: describe    Cyanotic Heart Disease: diagnosis    Airway/Neuro-muscular Conditions:    < 12 months of age at start of season and compromised handling of secretions AND due to    Significant abnormality of the airway (attach clinical notes)   Neuromuscular condition (attach clinical notes)    Prematurity:   < GA 28 wks, 6 days AND < 12 months at start of season    Other conditions:   Other medical history (describe)    PRESCRIPTION INFORMATION    MEDICATION   STRENGTH   DOSE & DIRECTIONS   Quantity: QS to general part of the part of the policy of th                             |            |
| (meds/dates)   |            |
| Moderate to severe pulmonary hypertension   Other: describe  |            |
| □ Other: describe     □ < 24 months of age undergoing cardiac transplantation during the RSV season (date)     □ Cyanotic Heart Disease: diagnosis     □ Airway/Neuro-muscular Conditions:     □ < 12 months of age at start of season and compromised handling of secretions AND due to     □ Significant abnormality of the airway (attach clinical notes)    □ Neuromuscular condition (attach clinical notes)  Prematurity:    □ < GA 28 wks, 6 days AND < 12 months at start of season  Other conditions:    □ Other medical history (describe)  SPRESCRIPTION INFORMATION  MEDICATION  STRENGTH  DOSE & DIRECTIONS  QUANTITY/R  Quantity: QS to spring 15 mg/kg IM one time per month  |            |
| ☐ Cyanotic Heart Disease: diagnosis  |            |
| ☐ Cyanotic Heart Disease: diagnosis  |            |
| Airway/Neuro-muscular Conditions: <pre></pre>  |            |
| ☐ < 12 months of age at start of season and compromised handling of secretions AND due to ☐ Significant abnormality of the airway (attach clinical notes) ☐ Neuromuscular condition (attach clinical notes)  Prematurity: ☐ < GA 28 wks, 6 days AND < 12 months at start of season  Other conditions: ☐ Other medical history (describe)   |            |
| Significant abnormality of the airway (attach clinical notes)  □ Neuromuscular condition (attach clinical notes)  Prematurity: □ < GA 28 wks, 6 days AND < 12 months at start of season  Other conditions: □ Other medical history (describe) □  PRESCRIPTION INFORMATION  MEDICATION STRENGTH DOSE & DIRECTIONS QUANTITY/R  □ Synagis □ Inject 15 mg/kg IM one time per month   |            |
| Prematurity:   < GA 28 wks, 6 days AND < 12 months at start of season  Other conditions:   Other medical history (describe)    PRESCRIPTION INFORMATION  MEDICATION   STRENGTH   DOSE & DIRECTIONS   QUANTITY/R    Synagis   So mg and/or 100 mg vials   Inject 15 mg/kg IM one time per month   Sphiole 15 mg/kg IM one time per mo |            |
| Other conditions:  Other medical history (describe)  PRESCRIPTION INFORMATION  MEDICATION  STRENGTH  DOSE & DIRECTIONS  QUANTITY/R  Quantity: QS to Spingles  50 mg and/or 100 mg viels  Unject 15 mg/kg IM one time per month   |            |
| PRESCRIPTION INFORMATION  MEDICATION STRENGTH DOSE & DIRECTIONS QUANTITY/R  Synagis Inject 15 mg/kg IM one time per month  |            |
| MEDICATION         STRENGTH         DOSE & DIRECTIONS         QUANTITY/R           □ Synagis         □ Inject 15 mg/kg IM one time per month         Quantity: QS to period 15 mg/kg IM one time per month   |            |
| Synagis  Synagis  Synagis  So mg and/or 100 mg yiels  Inject 15 mg/kg IM one time per month  Sphious 15 mg/kg  Quantity: QS to   |            |
| 50 mg and/or 100 mg yiels   Inject 15 mg/kg IM one time per month   pobiovo 15 mg/kg   |            |
|  |            |
| (DailyiZuillau)  |            |
| Refills:   |            |
| Epinephrine 1:1000 amp Inject 0.01 mg/kg SC as directed for Quantity:  |            |
| anaphylaxis Refills: 0   |            |
| Patient is interested in patient support programs  STAMP SIGNATURE NOT ALLOWED  Ancillary supplies and kits provided as needed for PHYSICIAN SIGNATURE REQUIRED  | administra |
| PRODUCT SUBSTITUTION PERMITTED (Date) DISPENSE AS WRITTEN (Date)   | !          |
| XX  The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the nation's medical record.   |            |

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any sender immediately by telephone and destroy all copies of this communication and any attachments.